1) Strategy & Leadership - IQVIA Holdings Inc. reported record first-quarter revenue and adjusted diluted EPS, exceeding guidance. - CEO Ari Bousbib highlighted strong organic revenue growth, particularly in Commercial Solutions and R&D Solutions, with organic growth rates doubling and tripling respectively. - The company is leveraging AI to enhance service offerings, with 192 AI agents deployed across 64 use cases, indicating a strong commitment to innovation.

2) Financial & Segment Results - Total revenue for Q1 2026 was $4.151 billion, reflecting an 8.4% increase YoY (6% at constant currency). - Adjusted EBITDA rose by 5.5%, while adjusted diluted EPS increased by 7.4% to $2.90. - Segment performance: | Segment | Revenue (Q1 2026) | YoY Growth (Reported) | YoY Growth (Constant Currency) | |----------------------|-------------------|-----------------------|---------------------------------| | Commercial Solutions | $1.754 billion | 11.6% | 8.5% | | R&D Solutions | $2.397 billion | 6.2% | 4.2% |

3) Problems / Headwinds - The book-to-bill ratio was 1.04, attributed to unusually low pass-through bookings due to the mix of clinical trials, not indicative of demand or profitability issues. - Pass-through bookings were significantly lower than historical averages, impacting the perceived strength of bookings but not margins. - The company noted ongoing macroeconomic challenges affecting client decision-making speed, although demand indicators are improving.

4) Operational or Product Plans - IQVIA is focused on integrating AI into its operations, enhancing efficiency and execution in clinical trials. - The company has secured several strategic partnerships, including collaborations with Pfizer and Boehringer Ingelheim, to leverage AI in commercial operations. - Continued investment in AI capabilities is expected to drive future growth, with a strong pipeline of new drug launches and clinical trials anticipated.

5) Guidance & Outlook / Investor Angle - IQVIA reaffirmed its full-year 2026 guidance for revenue ($17.15 billion to $17.35 billion) and adjusted EBITDA ($4.05 billion to $4.25 billion), while raising adjusted diluted EPS guidance to $12.65 to $12.95. - For Q2 2026, revenue is expected to be between $4.28 billion and $4.34 billion, indicating YoY growth of 6.5% to 8%. - The outlook remains positive, with strong demand metrics and a record backlog of $34.2 billion.

Bottom line: IQVIA's strong Q1 performance, driven by robust organic growth and strategic AI integration, positions the company favorably for continued success. The reaffirmed guidance and positive demand indicators suggest a solid investment opportunity for shareholders.